title: The resurgence of thyromimetics as lipid-modifying agents.
abstract: The aggressive reduction of LDL-cholesterol levels by treatment with statins is a key component of preventive cardiovascular care; however, additional therapies to prevent atherosclerosis and the associated clinical sequelae are still needed. Thyromimetic compounds selective for the liver or for the thyroid hormone receptor isoform beta1 constitute a novel approach for the treatment of dyslipidemia. In preclinical studies, selective thyromimetics significantly reduced plasma cholesterol levels and provided protection from atherosclerosis by upregulating the hepatic LDL receptor and promoting reverse cholesterol transport. Importantly, data from ongoing clinical trials have provided the first evidence that selective thyromimetics may also reduce the levels of plasma cholesterol in humans.
authors.affiliation: Innsbruck Medical University, Department of Internal Medicine, Anichstrasse 35, Innsbruck 6020, Austria. ivan.tancevski@i-med.ac.at
authors.forename: Ivan
authors.initials: I
authors.lastname: Tancevski
authors.forename: Philipp
authors.initials: P
authors.lastname: Eller
authors.forename: Josef R
authors.initials: JR
authors.lastname: Patsch
authors.forename: Andreas
authors.initials: A
authors.lastname: Ritsch
mesh_terms: D000085:Acetates / Q000737:chemistry / Q000494:pharmacology; D000813:Anilides / Q000737:chemistry / Q000494:pharmacology; D000818:Animals; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D001161:Arteriosclerosis / Q000188:drug therapy / Q000517:prevention & control; D050197:Atherosclerosis / Q000517:prevention & control; D001692:Biological Transport; D032701:Biomimetics; D008078:Cholesterol, LDL / Q000097:blood / Q000378:metabolism; D002986:Clinical Trials as Topic; D050171:Dyslipidemias / Q000188:drug therapy; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D050356:Lipid Metabolism; D008314:Malonates / Q000494:pharmacology; D015394:Molecular Structure; D063065:Organophosphonates / Q000737:chemistry / Q000494:pharmacology; D010636:Phenols / Q000737:chemistry / Q000494:pharmacology; D010647:Phenyl Ethers / Q000494:pharmacology; D010648:Phenylacetates / Q000494:pharmacology; D011422:Propionates / Q000494:pharmacology; D011724:Pyridazines / Q000494:pharmacology; D011973:Receptors, LDL / Q000378:metabolism; D013961:Thyroid Gland / Q000187:drug effects*; D013963:Thyroid Hormones / Q000378:metabolism*
chemical_list: C539547:2-((3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy)methyl)-4-(3-chlorophenyl)-2-oxido(1,3,2)dioxaphosphonane; C113777:2-amino-3-(3,5-dibromo-4-(4-hydroxy-3-(6-oxo-1,6-dihydro-pyridazin-3-ylmethyl)-phenoxyl)-phenyl)-propionic acid; C526273:3-((3,5-dibromo-4-(4-hydroxy-3-(1-methylethyl)phenoxy)phenyl)amino)-3-oxopropanoic acid; D000085:Acetates; D000813:Anilides; D000924:Anticholesteremic Agents; D008078:Cholesterol, LDL; C413355:GC 1 compound; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; C478108:KB 141; D008314:Malonates; C496199:N-(4-(3-((4-fluorophenyl)hydroxymethyl)-4-hydroxyphenoxy)-3,5-dimethylphenyl) malonamic acid sodium; D063065:Organophosphonates; D010636:Phenols; D010647:Phenyl Ethers; D010648:Phenylacetates; D011422:Propionates; D011724:Pyridazines; D011973:Receptors, LDL; D013963:Thyroid Hormones
references.citation: Metabolism. 1954 May;3(3):218-27
references.pmid: 13165045
references.citation: Nat Rev Drug Discov. 2009 Apr;8(4):308-20
references.pmid: 19337272
references.citation: Mol Pharmacol. 1997 Sep;52(3):542-7
references.pmid: 9281617
references.citation: Thyroid. 2008 Feb;18(2):239-53
references.pmid: 18279024
references.citation: Nature. 1986 Dec 18-31;324(6098):635-40
references.pmid: 2879242
references.citation: Endocrinology. 2004 Apr;145(4):1656-61
references.pmid: 14701670
references.citation: Mol Endocrinol. 2002 Aug;16(8):1767-77
references.pmid: 12145333
references.citation: Circulation. 2003 Aug 12;108(6):661-3
references.pmid: 12900335
references.citation: JAMA. 1972 May 15;220(7):996-1008
references.pmid: 4337170
references.citation: Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):663-7
references.pmid: 18160532
references.citation: Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10297-302
references.pmid: 16006512
references.citation: Br J Pharmacol. 2009 Feb;156(3):454-65
references.pmid: 19183199
references.citation: Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):10067-72
references.pmid: 12888625
references.citation: Endocrinology. 1990 Sep;127(3):1144-52
references.pmid: 2387252
references.citation: Biochem Biophys Res Commun. 1998 Aug 19;249(2):517-21
references.pmid: 9712728
references.citation: Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15490-5
references.pmid: 17878314
references.citation: J Clin Endocrinol Metab. 1955 Jan;15(1):73-80
references.pmid: 13221629
references.citation: J Steroid Biochem Mol Biol. 2001 Jan-Mar;76(1-5):31-42
references.pmid: 11384861
references.citation: Endocr Rev. 1993 Apr;14(2):184-93
references.pmid: 8325251
references.citation: Curr Opin Lipidol. 2003 Apr;14(2):173-9
references.pmid: 12642786
references.citation: Nature. 1986 Dec 18-31;324(6098):641-6
references.pmid: 2879243
references.citation: Clin Exp Pharmacol Physiol Suppl. 1998 Nov;25:S2-11
references.pmid: 9809185
references.citation: J Mol Med (Berl). 2005 Nov;83(11):927-32
references.pmid: 16133421
references.citation: Circulation. 2007 Sep 11;116(11):1267-73
references.pmid: 17709636
references.citation: J Mol Cell Cardiol. 2004 Dec;37(6):1137-46
references.pmid: 15572044
references.citation: Lancet. 1957 Jan 19;272(6960):120-3
references.pmid: 13399145
references.citation: Biochem J. 1991 Jun 15;276 ( Pt 3):825-32
references.pmid: 2064617
references.citation: Am J Physiol. 1998 Aug;275(2):R640-6
references.pmid: 9688704
references.citation: Circulation. 2006 May 30;113(21):2548-55
references.pmid: 16735689
references.citation: Endocrinology. 2001 Feb;142(2):544-50
references.pmid: 11159823
references.citation: N Engl J Med. 2005 Jan 6;352(1):29-38
references.pmid: 15635110
references.citation: J Lipid Res. 2009 May;50(5):938-44
references.pmid: 19106072
references.citation: Clin Pharmacol Ther. 1984 Dec;36(6):781-7
references.pmid: 6499357
references.citation: Nature. 1986 Dec 4-10;324(6096):425-9
references.pmid: 3785422
references.citation: Pharmacol Rev. 2006 Dec;58(4):705-11
references.pmid: 17132849
references.citation: J Med Chem. 1988 Jan;31(1):37-54
references.pmid: 3336030